Home » Stocks » Coherus BioSciences

Coherus BioSciences, Inc. (CHRS)

Stock Price: $19.46 USD 0.56 (2.96%)
Updated Aug 13, 2020 4:00 PM EDT - Market closed
After-hours: $19.44 -0.02 (-0.10%) Aug 13, 7:58 PM

Stock Price Chart

Key Info

Market Cap 1.39B
Revenue (ttm) 487.39M
Net Income (ttm) 180.87M
Shares Out 71.47M
EPS (ttm) 2.37
PE Ratio 8.21
Forward PE 11.48
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 13, 2020
Last Price $19.46
Previous Close $18.90
Change ($) 0.56
Change (%) 2.96%
Day's Open 18.80
Day's Range 18.80 - 19.55
Day's Volume 916,584
52-Week Range 10.86 - 23.91

More Stats

Market Cap 1.39B
Enterprise Value 1.35B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 71.47M
Float 63.26M
EPS (basic) 2.56
EPS (diluted) 2.37
FCF / Share 1.98
Dividend n/a
Dividend Yield n/a
Earnings Yield 12.18%
FCF Yield 10.14%
Payout Ratio n/a
Shares Short 18.92M
Short Ratio 19.49
Short % of Float 32.17%
Beta 2.02
PE Ratio 8.21
Forward PE 11.48
P/FCF Ratio 9.86
PS Ratio 2.85
PB Ratio 6.58
Revenue 487.39M
Operating Income 203.05M
Net Income 180.87M
Free Cash Flow 141.02M
Net Cash 43.13M
Net Cash / Share 0.60
Gross Margin 50.25%
Operating Margin 41.66%
Profit Margin 37.10%
FCF Margin 28.93%
ROA 25.47%
ROE 172.76%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (10)

Buy 8
Overweight 1
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$30.90*
(58.79% upside)
Low
22.0
Current: $19.46
High
35.0
Target: 30.90
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue356-1.5619030.0431.112.751.90
Revenue Growth---99.18%532.82%-3.42%1030.72%44.87%-
Gross Profit339-1.5619030.0431.112.751.90
Operating Income108-204-232-116-219-64.68-35.99-38.52
Net Income89.83-209-238-127-223-87.13-53.64-33.02
Shares Outstanding69.6865.0353.1341.9137.128.193.332.08
Earnings Per Share1.23-3.22-4.48-3.04-6.01-10.64-16.10-15.85
Operating Cash Flow28.36-159-200-253-108-23.9315.42-18.25
Capital Expenditures-1.82-0.79-4.57-6.52-6.16-2.85-0.37-1.78
Free Cash Flow26.53-160-205-259-114-26.7815.05-20.03
Cash & Equivalents17872.4112712515815239.710.00
Total Debt189103102100--4.20-
Net Cash / Debt-10.97-30.6925.3624.7515815235.510.00
Assets40999.4716317821218747.45-
Liabilities30413813215921912089.83-
Book Value105-38.5931.8220.53-6.2166.80-97.08-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Coherus BioSciences, Inc.
Country United States
Employees 306
CEO Denny M. Lanfear

Stock Information

Ticker Symbol CHRS
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CHRS
IPO Date November 6, 2014

Description

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte stimulating colony factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States. Its product candidates include CHS-1420, an adalimumab (Humira) biosimilar candidate and CHS-0214, an etanercept (Enbrel) biosimilar candidate, which have completed Phase III clinical study for treating psoriasis and rheumatoid arthritis. The company is also developing ranibizumab (Lucentis), an ophthalmology biosimilar candidate; CHS-2020, an aflibercept (Eylea) biosimilar candidate; and CHS-131, a small-molecule drug candidate for non-alcoholic steatohepatitis and other metabolic conditions, as well as bevacizumab (Avastin), an oncology biosimilar candidate. Coherus BioSciences, Inc. has license agreements with Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; Daiichi Sankyo Company, Limited; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.